Previously, we have shown that PR1-CTL are found in most patients that achieve remission while being treated with IFN and that these PR1-CTL contribute to remission by killing CML cells [16]. This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.